Scientific innovation is transforming atopic eczema treatment. But developing new medicines is only part of the story. For patients, innovation matters only when effective treatments can actually be accessed.
That is the message the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) is bringing directly into the development of Europe's new biotechnology legislation.
In September 2026, EFA published its response to the European Commission's proposed European Biotech Act, outlining three patient priorities that it believes should not be overlooked as European policymakers shape the new legislation. The proposed Act is intended to strengthen Europe's biotechnology sector and encourage innovation.
EFA supports that ambition — but argues that competitiveness should not become the only measure of success. For people living with conditions such as atopic eczema, the more important question is whether scientific progress ultimately leads to safe, effective and affordable treatment. EFA therefore identified access as one of its main priorities.
Biological medicines and other biotechnology-based treatments have already transformed care for several chronic inflammatory conditions, including atopic eczema. Yet availability differs significantly across European countries. A treatment may exist and be medically appropriate but remain unavailable to a patient because of reimbursement restrictions, delays in national decision-making, price or differences between healthcare systems. EFA argues that European biotechnology policy should consider those inequalities from the beginning.
Its second priority concerns meaningful patient involvement. Patients should not enter the process only after a technology has been developed. EFA is calling for patient perspectives to be integrated throughout research, development and policy decisions so that innovation addresses needs that genuinely matter to people living with chronic diseases. That can include issues that traditional research endpoints may not fully capture: treatment burden, ease of use, quality of life, long-term disease control and the practical realities of accessing care.
The third priority focuses on ensuring that biotechnology policy remains connected to public health needs. Europe may succeed in creating more innovative medicines, but EFA argues that innovation should ultimately improve outcomes for patients rather than simply strengthen markets.
This is an important example of what modern patient advocacy looks like. Patient organisations are not only raising awareness about disease. They are increasingly entering discussions about how research is funded, how medicines are developed, how technologies are assessed and whether patients can afford or access the results. For the atopic eczema community, those discussions are particularly timely.
Treatment possibilities have expanded enormously in recent years, but access remains uneven across Europe. A medicine that changes one patient's life may still be effectively out of reach for another patient living only a few borders away.
EFA's intervention therefore puts a simple patient-centred principle into a much larger European policy debate:
Innovation should not be measured only by what science can create, but by whether the people who need that innovation can actually benefit from it.